Active Not RecruitingNCT06196840
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
PHASE2 · 50 planned enrolment
- Countries listed
- 1
- Registry update
- March 6, 2026
immortal.lifeTrial registrations containing the exact intervention label LX102 subretinal injection.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 50 planned enrolment
PHASE1 · 12 planned enrolment